Daily Sepsis Research Analysis
Three mechanistic studies advance sepsis biology and potential therapeutics: TIM-3 is identified as a key immune checkpoint shaping CD4 T-cell responses under iron overload during Salmonella sepsis; MAO-A inhibition mitigates septic acute lung injury via Nrf2/HO-1 activation and pyroptosis suppression; and selective 11β-HSD1 blockade alleviates sepsis-induced cardiac dysfunction by steering macrophage polarization through AMPK/mTOR-mediated autophagy. These works provide convergent targets acros
Summary
Three mechanistic studies advance sepsis biology and potential therapeutics: TIM-3 is identified as a key immune checkpoint shaping CD4 T-cell responses under iron overload during Salmonella sepsis; MAO-A inhibition mitigates septic acute lung injury via Nrf2/HO-1 activation and pyroptosis suppression; and selective 11β-HSD1 blockade alleviates sepsis-induced cardiac dysfunction by steering macrophage polarization through AMPK/mTOR-mediated autophagy. These works provide convergent targets across immunity, oxidative stress, and cellular metabolism.
Research Themes
- Immune checkpoint regulation and iron metabolism in bacterial sepsis
- Oxidative stress, Nrf2/HO-1 signaling, and pyroptosis in septic organ injury
- Metabolic-autophagy pathways controlling macrophage polarization in sepsis-induced cardiomyopathy
Selected Articles
1. TIM-3 ameliorates host responses to Salmonella infection by controlling iron driven CD4
In a Salmonella sepsis model, dietary iron loading worsened survival, which was further exacerbated by TIM-3 deletion, indicating a protective, regulatory role for TIM-3. Mechanistically, TIM-3 loss increased IL-10 production due to impaired IL-12R-dependent CD4+ T cell responses, revealing treatable pathways in iron overload-associated infection.
Impact: This study uncovers a checkpoint mechanism linking iron overload to maladaptive CD4 T-cell responses in bacterial sepsis, identifying TIM-3 as a modifiable axis for host defense.
Clinical Implications: In patients with iron overload (e.g., hematologic malignancies), strategies that optimize iron management and cautiously target TIM-3-related pathways could reduce infection mortality, pending translational and clinical validation.
Key Findings
- Dietary iron supplementation reduced survival in Salmonella sepsis; TIM-3 deletion further worsened outcomes.
- TIM-3 deficiency increased IL-10 production due to impaired IL-12R-dependent CD4+ T cell responses.
- TIM-3 is a crucial regulator of T cell-driven immune control during bacterial infection, highlighting treatable pathways in iron overload syndromes.
Methodological Strengths
- Genetic deletion and dietary iron-loading in an in vivo sepsis model enable causal inference.
- Mechanistic dissection of cytokine signaling (IL-12R/IL-10) in CD4+ T cells.
Limitations
- Findings are limited to murine Salmonella sepsis and iron overload; generalizability to other pathogens and human disease needs validation.
- No interventional human data to support TIM-3 targeting in clinical sepsis.
Future Directions: Validate TIM-3 pathways in human cohorts with iron overload, define timing/risks of checkpoint modulation in infection, and explore combination with iron chelation strategies.
BACKGROUND: Iron loading increases infection risk in being a nutrient for invading siderophilic bacteria and by modulating immune functions including the expression of the immune checkpoint regulator T-cell immunoglobulin-and-mucin-containing-domain-3 (TIM-3). TIM-3 affects specific immune cell functions including T-helper cell differentiation but also T cell dysfunction, and immune exhaustion. Given the prevalence of iron overload specifically in patients at higher risk for infection such as those suffering from hemo-oncological diseases, we inve
2. MAO-A inhibition alleviates sepsis-driven lung injury via Nrf2/HO-1 pathway activation and suppression of pyroptosis.
MAO-A expression was upregulated in sepsis. Pharmacologic inhibition with RO11-11639 reduced oxidative stress (ROS, MDA), inflammation (e.g., IL-1β, IL-16), and pyroptosis in CLP-induced lung injury and in LPS-stimulated HPAEpiC. Mechanistically, benefits were mediated by Nrf2 nuclear translocation and activation of HO-1, NQO-1, and glutathione S-transferase, delineating a Nrf2/HO-1-centered pathway.
Impact: This work links a druggable mitochondrial enzyme (MAO-A) to septic lung injury via Nrf2/HO-1 and pyroptosis, offering a plausible repurposing avenue with multi-system validation.
Clinical Implications: MAO-A inhibitors could be explored as adjunctive therapies for septic acute lung injury, focusing on antioxidant and anti-pyroptotic effects; clinical dosing, safety, and efficacy require prospective trials.
Key Findings
- MAO-A is significantly upregulated in sepsis based on GEO datasets and clinical samples.
- RO11-11639 mitigated CLP-induced lung injury, reducing ROS, MDA, IL-1β, IL-16, and pyroptosis in vivo and in vitro.
- Mechanistic rescue experiments implicate Nrf2/HO-1 activation (Nrf2 nuclear translocation, HO-1, NQO-1, GST upregulation) as central to the protective effects.
Methodological Strengths
- Integrated evidence: bioinformatics, human samples, murine CLP model, and human alveolar epithelial cell assays.
- Pathway-level validation with functional rescue linking MAO-A inhibition to Nrf2/HO-1 activation and anti-pyroptosis.
Limitations
- Preclinical study without survival outcomes or human interventional data.
- Specific inhibitor profiling and off-target/toxicity assessments in humans are lacking.
Future Directions: Test MAO-A inhibition in additional polymicrobial sepsis models, integrate survival endpoints, and evaluate repurposable MAO-A inhibitors in early-phase clinical studies.
Extensive research has highlighted the involvement of excessive oxidative stress and pyroptosis in sepsis-caused acute lung injury (ALI). The present investigation delves into the potential role of Monoamine oxidase A (MAO-A) in this pathological process. Analyzing Gene Expression Omnibus (GEO) datasets alongside clinical samples revealed a significant upregulation of MAO-A in sepsis patients. To further elucidate this, cecal ligation puncture (CLP)-induced ALI were established in C57BL/6 mice. Additionally, human alveolar epithelial cells (HPAEpiC) treated with MAO-A inhibitor RO11-11639 were subjected to lipopolysaccharide (LPS) stimulation in vitro. The in-vivo experiments demonstrated that RO11-11639 mitigated CLP-
3. 11β-HSD1 inhibitor alleviates sepsis-induced cardiac dysfunction by regulating macrophage polarization via the AMPK/mTOR autophagy pathway.
In LPS-induced sepsis, preventive BVT.2733 improved cardiac function, reduced M1 macrophage infiltration and inflammation in heart and spleen, and decreased cardiomyocyte apoptosis in co-culture assays. Mechanistically, 11β-HSD1 inhibition activates AMPK/mTOR-dependent autophagy, steering macrophages away from the proinflammatory M1 phenotype.
Impact: Identifies 11β-HSD1 as a modifiable metabolic target to reduce SIMD by coupling macrophage polarization to autophagy signaling, pointing to a tractable therapeutic strategy.
Clinical Implications: 11β-HSD1 inhibitors warrant translational evaluation as adjunctive therapy for sepsis-induced myocardial dysfunction; timing (prevention vs. treatment), dosing, and safety in humans remain to be established.
Key Findings
- Preventive BVT.2733 ameliorated LPS-induced cardiac dysfunction and reduced M1 macrophage infiltration and inflammation in vivo.
- BVT.2733 inhibited M1 polarization and inflammatory responses in RAW264.7 cells; conditioned media reduced H9C2 apoptosis and injury.
- Mechanism: activation of AMPK/mTOR-dependent autophagy underlies the anti-inflammatory, cardioprotective effects of 11β-HSD1 inhibition.
Methodological Strengths
- Combined in vivo and in vitro models with macrophage–cardiomyocyte co-culture to capture paracrine effects.
- Mechanistic linkage to AMPK/mTOR autophagy pathway strengthens causal inference.
Limitations
- LPS endotoxemia model may not recapitulate polymicrobial human sepsis; short-term preventive dosing limits translational inference.
- No survival endpoints or post-insult therapeutic testing were reported.
Future Directions: Evaluate therapeutic (post-insult) dosing, include survival and hemodynamic endpoints, and test in polymicrobial CLP models and large animals before early-phase trials.
OBJECTIVES: Myocardial dysfunction is the most serious complication of sepsis. Sepsis-induced myocardial dysfunction (SIMD) is often associated with an excessive inflammatory response within the cardiac tissue. Targeted inhibition of the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) attenuates local tissue inflammatory responses. We investigated the efficacy of 11β-HSD1 blockade as a potential new treatment in SIMD. METHODS: In mice, sepsis was established by intraperitoneally injecting lipopolysaccharide (LPS, 10 mg/kg). Subsequently, the effects of 11β-HSD1 selective inhibitor BVT.2733 administration on LPS-triggered cardiac dysfunction, macrophage infiltration, and spleen inflammation in mice were investigated. In in vitro studies, the macrophage cell line RAW264.7 was used to assess the effect and molecular mechanism of BVT.2733 (50 or 100 μM) on LPS-induced polarization and inflammation. Furthermore, the supernatant of macrophages was collected after intervention and co-cultured with the H9C2 cell line to assess cardiomyocyte apoptosis and injury. RESULTS: The preventive administration of BVT.2733 can ameliorate cardiac dysfunction, M1 macrophage infiltration, and cardiac inflammation induced by LPS. The findings also demonstrated that BVT.2733 exhibited a mitigating effect on spleen pathological injury and inflammatory responses. Subsequently, BVT.2733 demonstrated the ability to inhibit M1 polarization of macrophages and attenuate inflammatory response in vitro. Meanwhile, our findings showed that BVT.2733 administration effectively mitigated inflammation and apoptosis in H9C2 cells in the proinflammatory environment produced by macrophages. Mechanistic studies revealed that BVT.2733 elevated autophagy levels by activating the AMPK/mTOR signaling pathway. CONCLUSION: The 11β-HSD1 selective inhibitor BVT.2733 demonstrates potential in ameliorating cardiac dysfunction and myocardial injury in septic mice induced by LPS. This beneficial effect is likely attributed to the modulation of macrophage polarization through the AMPK/mTOR autophagy pathway.